

## Fusilev<sup>®</sup> (levoleucovorin)

Document Number: IC-0183

Last Review Date: 5/1/2018

Date of Origin: 01/02/2014

Dates Reviewed: 08/2014, 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017, 05/2017, 08/2017, 11/2017, 2/2018, 5/2018

### I. Length of Authorization

Coverage will be provided for ninety days and may be renewed.

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [Pharmacy Benefit]:

- Fusilev 50 mg powder for injection: 25 vials per 28 days
- Fusilev 175 mg/17.5 mL injection: 8 vials per 28 days
- Fusilev 250 mg/25 mL injection: 5 vials per 28 days

#### B. Max Units (per dose and over time) [Medical Benefit]:

In combination with methotrexate or for inadvertent overdose

- 1,200 billable units every 28 days

In combination with fluorouracil

- 2,500 billable units every 28 days

### III. Initial Approval Criteria

Coverage is provided in the following conditions:

- Patient is at least 6 years old; **AND**
- Patient does not have pernicious anemia or vitamin B12 deficiency megaloblastic anemia; **AND**
- Racemic *d*,Fleucovorin calcium is not obtainable (in any dosage strength) as confirmed by FDA Drug shortage website located at:  
<http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>; **AND**

**Bone Cancer (Osteosarcoma †, Dedifferentiated Chondrosarcoma ‡, High-Grade Undifferentiated Pleomorphic Sarcoma (UPS) ‡)**

- Patient is undergoing high-dose methotrexate chemotherapy treatment; **AND**
- Must be used as rescue therapy in combination with chemotherapy regimen containing high dose methotrexate

**Reduction of toxicity due to impaired elimination or inadvertent overdose with folic acid antagonists †**

- Patient is undergoing treatment with a folic acid antagonist, such as methotrexate; **AND**

- Patient has developed toxicity due to impaired elimination or inadvertent overdosage of the folic acid antagonist (i.e., methotrexate)

**Colorectal cancer † ‡**

- Must be used in combination with fluorouracil-based regimens

**Used in combination with high-dose methotrexate for the following ‡**

- Acute Lymphoblastic Leukemia
- AIDS-related B-cell Lymphoma
- Burkitt Lymphoma
- Mantle Cell Lymphoma
- CNS Cancer (Primary CNS Lymphoma, Brain Metastases, & Leptomeningeal Metastases)
- Peripheral T-cell Lymphoma
- Adult T-cell Leukemia/Lymphoma
- Extranodal NK/T-cell Lymphoma (nasal type)

**Used in combination with fluorouracil-based regimens for the following ‡**

- Anal Carcinoma
- Bladder Cancer (non-urothelial and urothelial with variant histology)
- Cervical Cancer
- Esophageal, Esophagogastric Junction, & Gastric Cancer
- Neuroendocrine and Adrenal Tumors
- Occult Primary
- Ovarian/Fallopian Tube/Primary Peritoneal Mucinous Carcinomas
- Pancreatic Adenocarcinoma
- Thymoma and Thymic Carcinoma

† FDA labeled indication(s); ‡ Compendia recommended indication(s)

#### **IV. Renewal Criteria**

Coverage can be renewed based upon the following criteria:

- Patient continues to meet the criteria in section III; **AND**
- Racemic *d*,Fleucovorin calcium is not obtainable (in any dosage strength) as confirmed by FDA Drug shortage website located at:  
<http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>; **AND**

- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: hypersensitivity reactions, seizures, and severe gastrointestinal disorders such as stomatitis, severe diarrhea, and severe nausea and vomiting.

## V. Dosage/Administration

Fusilev is dosed at **one-half** the usual dose of racemic *d, l*-leucovorin

| Indication  | Dose   |
|---|--|
| In combination with high-dose methotrexate  | 7.5 mg (approximately 5 mg/m <sup>2</sup> ) IV every 6 hours for 10 doses starting 24 hours after beginning of methotrexate infusion. Dosing is based on a methotrexate dose of 12 grams/m <sup>2</sup> administered by intravenous infusion over 4 hours. Continue until methotrexate levels are less than 5 x 10 <sup>-8</sup> M (0.05 micromolar)   |
| Reduction of toxicity due to impaired elimination or inadvertent overdose with folic acid antagonists | Methotrexate over dosage: 7.5 mg (approximately 5 mg/m <sup>2</sup> ) IV every 6 hours until methotrexate levels are less than 10 <sup>-8</sup> M (0.01 micromolar)  |
| In combination with 5-FU  | <p>100 mg/m<sup>2</sup> administered by slow intravenous injection over a minimum of 3 minutes, followed by 5-FU at 370 mg/m<sup>2</sup> by intravenous injection.</p> <p><b>OR</b></p> <p>10 mg/m<sup>2</sup> administered by intravenous injection followed by 5-FU at 425 mg/m<sup>2</sup> by intravenous injection.</p> <p>Treatment is repeated daily for five days. This five-day treatment course may be repeated at 4-week (28-day) intervals, for 2 courses and then repeated at 4 to 5 week (28 to 35 day) intervals provided that the patient has completely recovered from the toxic effects of the prior treatment course.</p> <p><u>Alternate Dosing Regimen</u></p> <p>200 mg/m<sup>2</sup> administered by intravenous injection DAY 1 followed by 5-FU 400 mg/m<sup>2</sup> bolus on DAY 1, then 5-FU 1200 mg/m<sup>2</sup> /day x 2 days IV continuous infusion; repeat every 14 days.</p> |

## VI. Billing Code/Availability Information

Jcode:

- J0641 – Injection, levoleucovorin calcium, 0.5 mg = 1 billable unit

NDC:

- Fusilev 50 mg single-use vial powder for injection: 68152-0101-xx
- Fusilev 10 mg/mL single-use vial (175 mg/17.5 mL; 250 mg/25 mL) injection: 68152-0102-xx

*\*generics available through various manufacturers*

## VII. References

1. Fusilev [package insert]. Irvine, CA; Spectrum Pharmaceuticals, Inc; April 2011. Accessed April 2018.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) levoleucovorin. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2018.
3. Goorin A, Strother D, Poplack D, et al. Safety and efficacy of l-leucovorin rescue following high-dose methotrexate for osteosarcoma. Med Pediatr Oncol. 1995 Jun; 24(6):362-7.

### Appendix 1 – Covered Diagnosis Codes

| ICD-10 | ICD-10 Description  |
|--------|---|
| C15.3  | Malignant neoplasm of upper third of esophagus                  |
| C15.4  | Malignant neoplasm of middle third of esophagus                 |
| C15.5  | Malignant neoplasm of the lower third of esophagus              |
| C15.8  | Malignant neoplasm of overlapping sites of esophagus            |
| C15.9  | Malignant neoplasm of esophagus, unspecified                    |
| C16.0  | Malignant neoplasm of cardia                                    |
| C16.1  | Malignant neoplasm of fundus of stomach                         |
| C16.2  | Malignant neoplasm of body of stomach                           |
| C16.3  | Malignant neoplasm of pyloric antrum                            |
| C16.4  | Malignant neoplasm of pylorus                                   |
| C16.5  | Malignant neoplasm of lesser curvature of stomach, unspecified  |
| C16.6  | Malignant neoplasm of greater curvature of stomach, unspecified |
| C16.8  | Malignant neoplasm of overlapping sites of stomach              |
| C16.9  | Malignant neoplasm of stomach, unspecified                      |
| C17.0  | Malignant neoplasm of duodenum                                  |
| C17.1  | Malignant neoplasm of jejunum                                   |
| C17.2  | Malignant neoplasm of ileum                                     |
| C17.8  | Malignant neoplasm of overlapping sites of small intestine      |
| C17.9  | Malignant neoplasm of small intestine, unspecified              |
| C18.0  | Malignant neoplasm of cecum                                     |
| C18.1  | Malignant neoplasm of appendix                                  |
| C18.2  | Malignant neoplasm of ascending colon                           |
| C18.3  | Malignant neoplasm of hepatic flexure                           |
| C18.4  | Malignant neoplasm of transverse colon                          |
| C18.5  | Malignant neoplasm of splenic flexure                           |
| C18.6  | Malignant neoplasm of descending colon                          |

| ICD-10 | ICD-10 Description  |
|--------|---|
| C18.7  | Malignant neoplasm of sigmoid colon   |
| C18.8  | Malignant neoplasm of overlapping sites of colon  |
| C18.9  | Malignant neoplasm of colon, unspecified  |
| C19    | Malignant neoplasm of rectosigmoid junction   |
| C20    | Malignant neoplasm of rectum  |
| C21.0  | Malignant neoplasm of anus, unspecified   |
| C21.1  | Malignant neoplasm of anal canal  |
| C21.8  | Malignant neoplasm of overlapping sites of rectum, anus and anal canal                      |
| C25.0  | Malignant neoplasm of head of pancreas  |
| C25.1  | Malignant neoplasm of body of pancreas  |
| C25.2  | Malignant neoplasm of tail of pancreas  |
| C25.3  | Malignant neoplasm of pancreatic duct   |
| C25.7  | Malignant neoplasm of other parts of pancreas   |
| C25.8  | Malignant neoplasm of overlapping sites of pancreas   |
| C25.9  | Malignant neoplasm of pancreas, unspecified   |
| C37    | Malignant neoplasm of thymus  |
| C40.00 | Malignant neoplasm of scapula and long bones of unspecified upper limb                      |
| C40.01 | Malignant neoplasm of scapula and long bones of right upper limb                            |
| C40.02 | Malignant neoplasm of scapula and long bones of left upper limb                             |
| C40.10 | Malignant neoplasm of short bones of unspecified upper limb                                 |
| C40.11 | Malignant neoplasm of short bones of right upper limb                                       |
| C40.12 | Malignant neoplasm of short bones of left upper limb  |
| C40.20 | Malignant neoplasm of long bones of unspecified lower limb                                  |
| C40.21 | Malignant neoplasm of long bones of right lower limb  |
| C40.22 | Malignant neoplasm of long bones of left lower limb   |
| C40.30 | Malignant neoplasm of short bones of unspecified lower limb                                 |
| C40.31 | Malignant neoplasm of short bones of right lower limb                                       |
| C40.32 | Malignant neoplasm of short bones of left lower limb  |
| C40.80 | Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb |
| C40.81 | Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb       |
| C40.82 | Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb        |
| C40.90 | Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb         |
| C40.91 | Malignant neoplasm of unspecified bones and articular cartilage of right limb               |
| C40.92 | Malignant neoplasm of unspecified bones and articular cartilage of left limb                |
| C41.0  | Malignant neoplasm of bones of skull and face   |
| C41.1  | Malignant neoplasm of mandible  |
| C41.2  | Malignant neoplasm of vertebral column  |
| C41.3  | Malignant neoplasm of ribs, sternum and clavicle  |
| C41.4  | Malignant neoplasm of pelvic bones, sacrum and coccyx                                       |

| ICD-10 | ICD-10 Description  |
|--------|---|
| C41.9  | Malignant neoplasm of bone and articular cartilage, unspecified           |
| C48.1  | Malignant neoplasm of specified parts of peritoneum                       |
| C48.2  | Malignant neoplasm of peritoneum, unspecified                             |
| C48.8  | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| C53.0  | Malignant neoplasm of endocervix  |
| C53.1  | Malignant neoplasm of exocervix   |
| C53.8  | Malignant neoplasm of overlapping sites of cervix uteri                   |
| C53.9  | Malignant neoplasm of cervix uteri, unspecified                           |
| C56.1  | Malignant neoplasm of right ovary   |
| C56.2  | Malignant neoplasm of left ovary  |
| C56.9  | Malignant neoplasm of unspecified ovary                                   |
| C57.00 | Malignant neoplasm of unspecified fallopian tube                          |
| C57.01 | Malignant neoplasm of right fallopian tube                                |
| C57.02 | Malignant neoplasm of left fallopian tube                                 |
| C57.10 | Malignant neoplasm of unspecified broad ligament                          |
| C57.11 | Malignant neoplasm of right broad ligament                                |
| C57.12 | Malignant neoplasm of left broad ligament                                 |
| C57.20 | Malignant neoplasm of unspecified round ligament                          |
| C57.21 | Malignant neoplasm of right round ligament                                |
| C57.22 | Malignant neoplasm of left round ligament                                 |
| C57.3  | Malignant neoplasm of parametrium   |
| C57.4  | Malignant neoplasm of uterine adnexa, unspecified                         |
| C57.7  | Malignant neoplasm of other specified female genital organs               |
| C57.8  | Malignant neoplasm of overlapping sites of female genital organs          |
| C57.9  | Malignant neoplasm of female genital organ, unspecified                   |
| C67.0  | Malignant neoplasm of trigone of bladder                                  |
| C67.1  | Malignant neoplasm of dome of bladder                                     |
| C67.2  | Malignant neoplasm of lateral wall of bladder                             |
| C67.3  | Malignant neoplasm of anterior wall of bladder                            |
| C67.4  | Malignant neoplasm of posterior wall of bladder                           |
| C67.5  | Malignant neoplasm of bladder neck  |
| C67.6  | Malignant neoplasm of ureteric orifice                                    |
| C67.7  | Malignant neoplasm of urachus   |
| C67.8  | Malignant neoplasm of overlapping sites of bladder                        |
| C67.9  | Malignant neoplasm of bladder, unspecified                                |
| C78.00 | Secondary malignant neoplasm of unspecified lung                          |
| C78.01 | Secondary malignant neoplasm of right lung                                |
| C78.02 | Secondary malignant neoplasm of left lung                                 |
| C78.6  | Secondary malignant neoplasm of retroperitoneum and peritoneum            |
| C78.7  | Secondary malignant neoplasm of liver and intrahepatic bile duct          |

| ICD-10 | ICD-10 Description   |
|--------|--|
| C79.31 | Secondary malignant neoplasm of brain  |
| C79.32 | Secondary malignant neoplasm of cerebral meninges                            |
| C79.89 | Secondary malignant neoplasm of other specified sites                        |
| C79.9  | Secondary malignant neoplasm of unspecified site                             |
| C80.0  | Disseminated malignant neoplasm, unspecified                                 |
| C80.1  | Malignant (primary) neoplasm, unspecified                                    |
| C7A.1  | Malignant poorly differentiated neuroendocrine tumors                        |
| C7A.8  | Other malignant neuroendocrine tumors  |
| C7B.8  | Other secondary neuroendocrine tumors  |
| C83.10 | Mantle cell lymphoma, unspecified site                                       |
| C83.11 | Mantle cell lymphoma, lymph nodes of head, face and neck                     |
| C83.12 | Mantle cell lymphoma, intrathoracic lymph nodes                              |
| C83.13 | Mantle cell lymphoma, intra-abdominal lymph nodes                            |
| C83.14 | Mantle cell lymphoma, lymph nodes of axilla and upper limb                   |
| C83.15 | Mantle cell lymphoma, lymph nodes of inguinal region and lower limb          |
| C83.16 | Mantle cell lymphoma, intrapelvic lymph nodes                                |
| C83.17 | Mantle cell lymphoma, spleen   |
| C83.18 | Mantle cell lymphoma, lymph nodes of multiple sites                          |
| C83.19 | Mantle cell lymphoma, extranodal and solid organ sites                       |
| C83.30 | Diffuse large B-cell lymphoma unspecified site                               |
| C83.31 | Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck           |
| C83.32 | Diffuse large B-cell lymphoma intrathoracic lymph nodes                      |
| C83.33 | Diffuse large B-cell lymphoma intra-abdominal lymph nodes                    |
| C83.34 | Diffuse large B-cell lymphoma lymph nodes of axilla and upper limb           |
| C83.35 | Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.36 | Diffuse large B-cell lymphoma intrapelvic lymph nodes                        |
| C83.37 | Diffuse large B-cell lymphoma, spleen  |
| C83.38 | Diffuse large B-cell lymphoma lymph nodes of multiple sites                  |
| C83.39 | Diffuse large B-cell lymphoma extranodal and solid organ sites               |
| C83.70 | Burkitt lymphoma, unspecified site   |
| C83.71 | Burkitt lymphoma, lymph nodes of head, face, and neck                        |
| C83.72 | Burkitt lymphoma, intrathoracic lymph nodes                                  |
| C83.73 | Burkitt lymphoma, intra-abdominal lymph nodes                                |
| C83.74 | Burkitt lymphoma, lymph nodes of axilla and upper limb                       |
| C83.75 | Burkitt lymphoma, lymph nodes of inguinal region and lower limb              |
| C83.76 | Burkitt lymphoma, intrapelvic lymph nodes                                    |
| C83.77 | Burkitt lymphoma, spleen   |
| C83.78 | Burkitt lymphoma, lymph nodes of multiple sites                              |
| C83.79 | Burkitt lymphoma, extranodal and solid organ sites                           |
| C83.80 | Other non-follicular lymphoma, unspecified site                              |
| C83.81 | Other non-follicular lymphoma, lymph nodes of head, face and neck            |

| ICD-10 | ICD-10 Description  |
|--------|---|
| C83.82 | Other non-follicular lymphoma, intrathoracic lymph nodes                                    |
| C83.83 | Other non-follicular lymphoma, intra-abdominal lymph nodes                                  |
| C83.84 | Other non-follicular lymphoma, lymph nodes of axilla and upper limb                         |
| C83.85 | Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb                |
| C83.86 | Other non-follicular lymphoma, intrapelvic lymph nodes                                      |
| C83.87 | Other non-follicular lymphoma, spleen   |
| C83.88 | Other non-follicular lymphoma, lymph nodes of multiple sites                                |
| C83.89 | Other non-follicular lymphoma, extranodal and solid organ sites                             |
| C84.40 | Peripheral T-cell lymphoma, not classified, unspecified site                                |
| C84.41 | Peripheral T-cell lymphoma, not classified, lymph nodes of head, face, and neck             |
| C84.42 | Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes                       |
| C84.43 | Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes                     |
| C84.44 | Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb            |
| C84.45 | Peripheral T-cell lymphoma, not classified, lymph nodes of inguinal region and lower limb   |
| C84.46 | Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes                         |
| C84.47 | Peripheral T-cell lymphoma, not classified, spleen  |
| C84.48 | Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites                   |
| C84.49 | Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites                |
| C84.60 | Anaplastic large cell lymphoma, ALK-positive, unspecified site                              |
| C84.61 | Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck           |
| C84.62 | Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes                     |
| C84.63 | Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes                   |
| C84.64 | Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb          |
| C84.65 | Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb |
| C84.66 | Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes                       |
| C84.67 | Anaplastic large cell lymphoma, ALK-positive, spleen  |
| C84.68 | Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites                 |
| C84.69 | Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites              |
| C84.70 | Anaplastic large cell lymphoma, ALK-negative, unspecified site                              |
| C84.71 | Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neck           |
| C84.72 | Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes                     |
| C84.73 | Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes                   |
| C84.74 | Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb          |
| C84.75 | Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb |
| C84.76 | Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes                       |
| C84.77 | Anaplastic large cell lymphoma, ALK-negative, spleen  |
| C84.78 | Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites                 |
| C84.79 | Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites              |
| C84.90 | Mature T/NK-cell lymphomas, unspecified unspecified site                                    |
| C84.91 | Mature T/NK-cell lymphomas, unspecified lymph nodes of head, face, and neck                 |
| C84.92 | Mature T/NK-cell lymphomas, unspecified intrathoracic lymph nodes                           |



| ICD-10   | ICD-10 Description  |
|----------|---|
| C84.93   | Mature T/NK-cell lymphomas, unspecified intra-abdominal lymph nodes                         |
| C84.94   | Mature T/NK-cell lymphomas, unspecified lymph nodes of axilla and upper limb                |
| C84.95   | Mature T/NK-cell lymphomas, unspecified lymph nodes of inguinal region and lower limb       |
| C84.96   | Mature T/NK-cell lymphomas, unspecified intrapelvic lymph nodes                             |
| C84.97   | Mature T/NK-cell lymphomas, unspecified spleen  |
| C84.98   | Mature T/NK-cell lymphomas, unspecified lymph nodes of multiple sites                       |
| C84.99   | Mature T/NK-cell lymphomas, unspecified extranodal and solid organ sites                    |
| C84.Z0   | Other mature T/NK-cell lymphomas unspecified site   |
| C84.Z1   | Other mature T/NK-cell lymphomas lymph nodes of head, face, and neck                        |
| C84.Z2   | Other mature T/NK-cell lymphomas intrathoracic lymph nodes                                  |
| C84.Z3   | Other mature T/NK-cell lymphomas intra-abdominal lymph nodes                                |
| C84.Z4   | Other mature T/NK-cell lymphomas lymph nodes of axilla and upper limb                       |
| C84.Z5   | Other mature T/NK-cell lymphomas lymph nodes of inguinal region and lower limb              |
| C84.Z6   | Other mature T/NK-cell lymphomas intrapelvic lymph nodes                                    |
| C84.Z7   | Other mature T/NK-cell lymphomas spleen   |
| C84.Z8   | Other mature T/NK-cell lymphomas lymph nodes of multiple sites                              |
| C84.Z9   | Other mature T/NK-cell lymphomas extranodal and solid organ sites                           |
| C86.0    | Extranodal NK/T-cell lymphoma, nasal type   |
| C86.2    | Enteropathy-type (intestinal) T-cell lymphoma   |
| C86.5    | Angioimmunoblastic T-cell lymphoma  |
| C91.00   | Acute lymphoblastic leukemia not having achieved remission                                  |
| C91.01   | Acute lymphoblastic leukemia, in remission  |
| C91.02   | Acute lymphoblastic leukemia, in relapse  |
| C91.50   | Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission            |
| C91.51   | Adult T-cell lymphoma/leukemia (HTLV-1-associated) in remission                             |
| C91.52   | Adult T-cell lymphoma/leukemia (HTLV-1-associated) in relapse                               |
| D09.0    | Carcinoma in situ of bladder  |
| D15.0    | Benign neoplasm of thymus   |
| D37.1    | Neoplasm of uncertain behavior of stomach   |
| D37.8    | Neoplasm of uncertain behavior of other specified digestive organs                          |
| D37.9    | Neoplasm of uncertain behavior of digestive organ, unspecified                              |
| T39.4X5A | Adverse effect of antirheumatics, not elsewhere classified, initial encounter               |
| T45.1X5A | Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter             |
| T45.8X5A | Adverse effect of other primarily systemic and hematological agents, initial encounter      |
| T45.95XA | Adverse effect of unspecified primarily systemic and hematological agent, initial encounter |
| T50.995A | Adverse effect of other drugs, medicaments and biological substances, initial encounter     |
| Z80.49   | Family history of malignant neoplasm of other genital organs                                |
| Z85.00   | Personal history of malignant neoplasm of unspecified digestive organ                       |
| Z85.01   | Personal history of malignant neoplasm of esophagus   |
| Z85.028  | Personal history of other malignant neoplasm of stomach                                     |

| ICD-10  | ICD-10 Description   |
|---------|--|
| Z85.038 | Personal history of other malignant neoplasm of large intestine  |
| Z85.068 | Personal history of other malignant neoplasm of small intestine  |
| Z85.07  | Personal history of malignant neoplasm of pancreas               |
| Z85.51  | Personal history of malignant neoplasm of bladder                |
| Z85.72  | Personal history of non-Hodgkin lymphomas                        |
| Z85.830 | Personal history of malignant neoplasm of bone                   |
| Z85.858 | Personal history of malignant neoplasm of other endocrine glands |

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD): N/A

| Medicare Part B Administrative Contractor (MAC) Jurisdictions |   |   |
|---|---|---|
| Jurisdiction  | Applicable State/US Territory   | Contractor  |
| E (1)   | CA, HI, NV, AS, GU, CNMI  | Noridian Healthcare Solutions, LLC                |
| F (2 & 3)   | AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ  | Noridian Healthcare Solutions, LLC                |
| 5   | KS, NE, IA, MO  | Wisconsin Physicians Service Insurance Corp (WPS) |
| 6   | MN, WI, IL  | National Government Services, Inc. (NGS)          |
| H (4 & 7)   | LA, AR, MS, TX, OK, CO, NM  | Novitas Solutions, Inc.                           |
| 8   | MI, IN  | Wisconsin Physicians Service Insurance Corp (WPS) |
| N (9)   | FL, PR, VI  | First Coast Service Options, Inc.                 |
| J (10)  | TN, GA, AL  | Palmetto GBA, LLC                                 |
| M (11)  | NC, SC, WV, VA (excluding below)  | Palmetto GBA, LLC                                 |
| L (12)  | DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA) | Novitas Solutions, Inc.                           |
| K (13 & 14)   | NY, CT, MA, RI, VT, ME, NH  | National Government Services, Inc. (NGS)          |
| 15  | KY, OH  | CGS Administrators, LLC                           |